Ascendis Pharma A/S ASND
259.28 USD +2.69 (+1.05%)
At closeNov 12, 2026, 4:01 AM EST
263.99 +4.71 +1.82%
Pre-market · Nov 12, 4:01 AM ET
255.85 Day range 261.53
188.07 52-week range 282.15
- YTD
- +21.59%
- 1 year
- +28.89%
Benzinga news
benzinga.com Cisco Systems, Applied Materials On Deck Thursday As AI Demand Faces Test Cisco Systems and Applied Materials headline Thursday’s reports, with investors looking for evidence that AI infrastructure demand can keep supporting semiconductor and networking growth. Brookfield,…
benzinga.com Ascendis Pharma Says COMP Of EMA Adopts Positive Opinion Recommending Maintenance Of Orphan Medicinal Product Designation For Once-Weekly TransCon CNP As Treatment For Achondroplasia In Children Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending…
benzinga.com Ascendis Pharma Reports Sustained Kidney Function Improvements Over 5-Years With TransCon PTH In Adults With Hypoparathyroidism Ascendis Pharma A/S (NASDAQ:ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with…
benzinga.com Ascendis Pharma Receives Positive Opinion From Committee For Medicinal Products For Human Use Of European Medicines Agency For Marketing Authorization Of TransCon CNP In EU To Treat Achondroplasia Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending…
benzinga.com Here’s How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 13.7% on an annualized basis producing an average annual return of 27.5%. Currently, Ascendis Pharma has a market…